Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of nine systematic review(s)/meta-analysis(es). ^[1-9]
• Peramivir demonstrated a significant reduction in time to alleviation of symptoms (TTAS) when compared to laninamivir (mean difference (MD) = -17.68 hours; 95% confidence interval (CI): -34.05 to -1.32) and also showed shorter TTAS compared to other neuraminidase inhibitors (MD = -11.214 hours; 95% CI: -19.119 to -3.310). However, no significant difference was observed in TTAS when peramivir was compared directly to oseltamivir.
• Peramivir was associated with a reduced duration of hospitalization by -1.73 days (95% CI: -3.33 to -0.13) for seasonal influenza compared to placebo or standard care, and it also decreased the time to resumption of usual activities by -43.5 hours (95% CI: -72.8 to -14.2) in young and middle-aged adults.
• Peramivir demonstrated a comparable safety profile to other neuraminidase inhibitors (NAIs), with no significant differences in adverse events (AEs) or serious adverse events (SAEs) relative to oseltamivir, zanamivir, and laninamivir; for AEs, the relative risk (RR) was 1.023 (95% CI: 0.717 to 1.460), and for SAEs, RR was 1.068 (95% CI: 0.702 to 1.625).
• There is no population types or subgroups information available in the reviewed studies.